Company / PP&E (Net)
Edwards Lifesciences PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$1.8B
FY2025
5-year range
$1.5B / $1.8B
FY2021-FY2025
Trend
+7.5%
vs FY2024
Sector context
#28 of 132
Health Care
What the data says
Edwards Lifesciences's pp&e (net) of $1.8B is higher than 79% of companies in the Health Care sector (FY2025). Improved from $1.7B to $1.8B over the past 2 years.
Based on SEC 10-K filings.
$1.8B in FY2025 with a 5-year CAGR of +5.4%. Top quartile in the Health Care sector.
Improved from $1.7B to $1.8B over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +3.5%
- 5-Year CAGR
- +5.4%
- 10-Year CAGR
- -
Sector benchmark
Top 21% in Health CareTop 21% of 132This company $1.8B Sector average $1.4B
▼
+26.3% above sector average
Key checks
Key Insights
- 5-year CAGR of +5.4%, indicating consistent growth.
- In FY2025, pp&e (net) increased 7.5% year-over-year.
- Ranks #28 out of 132 companies in the Health Care sector.
- Lowest pp&e (net) in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 3.16 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.8B | +7.5% |
| FY2024 | $1.7B | -3.6% |
| FY2023 | $1.7B | +7.1% |
| FY2022 | $1.6B | +5.6% |
| FY2021 | $1.5B | +10.9% |
| FY2020 | $1.4B | +31.6% |
| FY2019 | $1.1B | +22.2% |
| FY2018 | $867.5M | +27.6% |
| FY2017 | $679.7M | +17.2% |
| FY2016 | $580.0M | +20.2% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026